Bullish indicating open at $55-$60, IPO prices at $37
In a recent move, Amy E. Herr, a director at Bio-Techne Corp (NASDAQ:TECH), sold shares amounting to $122,690. The transaction occurred on February 14, 2025, with shares sold at an average price of $65.96 each. Following this sale, Herr’s direct ownership in the company stands at 1,040 shares. The stock, currently trading near its 52-week low of $61.16, has seen analyst price targets ranging from $75 to $95, according to InvestingPro data.
Additionally, Herr’s significant other acquired 1,976 shares through a transaction priced at $44.33 per share. This acquisition was part of a larger transaction involving the exercise of stock options. After these transactions, the total shares held indirectly by Herr’s significant other are 1,976. Bio-Techne, with a market capitalization of $10.3 billion, maintains strong financial health with a current ratio of 3.94 and has sustained dividend payments for 18 consecutive years.
These transactions are part of regular insider trading activities, providing insight into the trading behavior of company insiders. Investors often keep an eye on such activities for potential signals about the company’s future performance. For deeper insights into insider trading patterns and comprehensive analysis, InvestingPro subscribers can access detailed financial health scores and 10+ additional ProTips about Bio-Techne’s current market position.
In other recent news, Bio-Techne Corporation, a global life sciences company, introduced a Good Manufacturing Practice (GMP) grade transposase mRNA for its TcBuster genome engineering system. This development could potentially streamline the creation of cell-based therapies by facilitating gene editing without the use of viral vectors. The GMP TcBuster transposase is now available for purchase and is expected to provide a more direct route to clinical applications for treatments such as chimeric antigen receptor T-cell and T-cell receptor therapies.
Furthermore, Bio-Techne Corporation reported its Q4 2024 earnings, surpassing analyst expectations with an EPS of $0.42 against a forecast of $0.39. The company also reported revenue of $297 million, exceeding the anticipated $286.14 million. Bio-Techne’s Q4 2024 total revenue increased by 4% year-over-year, and the company also reported a 5% growth in net gross profit, reaching $95 million.
These are recent developments that highlight Bio-Techne’s continued growth and innovation in the life sciences sector. The company’s advancements in cell therapy development and its strong financial performance underscore its commitment to scientific research and clinical diagnostics.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.